



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

American Journal of Infection Control

journal homepage: www.ajicjournal.org

Brief Report

Reduction and persistence of co-circulating respiratory viruses during the SARS-CoV-2 pandemic



Jason R. Smedberg PhD^a, Lauren M. DiBiase MS^b, Shawn E. Hawken PhD, MPH^a, Anika Allen BS^a, Suniti Mohan BS^c, Courtney Santos BS^a, Tandy Smedberg BA^d, Amir H. Barzin DO, MS^e, David A. Wohl MD^f, Melissa B. Miller PhD^{a,g,*}

^a Clinical Microbiology Laboratory, McLendon Clinical Laboratories, University of North Carolina Medical Center, Chapel Hill, NC

^b Department of Hospital Epidemiology, University of North Carolina Medical Center, Chapel Hill, NC

^c Department of Allied Health Sciences, UNC School of Medicine, Chapel Hill, NC

^d Department of Information Services, HonorBridge, Durham, NC

^e Department of Family Medicine, UNC School of Medicine, Chapel Hill, NC

^f Department of Medicine, Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC

^g Department of Pathology and Laboratory Medicine, UNC School of Medicine, Chapel Hill, NC

Key Words:

COVID-19

Respiratory viruses

Rhinovirus

Molecular respiratory panel

Syndromic testing

S U M M A R Y

To evaluate the co-circulation of respiratory viruses during the SARS-CoV-2 Alpha surge, we performed a molecular respiratory panel on 1,783 nasopharyngeal swabs collected between January 15 and April 15, 2021, from symptomatic outpatients that tested negative for SARS-CoV-2 in North Carolina. Of these, 373 (20.9%) were positive for at least 1 virus tested on the panel. Among positive tests, over 90% were positive for rhinovirus and/or enterovirus, either as a single infection or coinfection, illustrating persistent co-circulation of some respiratory viruses despite active infection control measures.

© 2022 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

BACKGROUND

During the COVID-19 pandemic, mitigation strategies have been instituted to decrease SARS-CoV-2 transmission. On an individual level, behaviors such as physical distancing, handwashing, and masking were adopted while prohibitions on mass gatherings, closing of indoor dining, and shifting students to virtual classrooms were implemented.

A consequence of these measures was a profound decrease in influenza cases. According to the Centers for Disease Control and Prevention, nationwide only 0.2% of respiratory specimens tested positive for influenza virus between September 28, 2020, and May 22, 2021.¹ In contrast, during the previous 3 influenza seasons peak positivity rates were 26.2%–30.3%.² This stark reduction in influenza circulation demonstrates the efficacy of mitigation measures to reduce transmission of influenza; however, it is unclear whether the efficacy

of these control strategies generalizes to other respiratory viruses ordinarily considered endemic during the period the study was conducted. To determine if other respiratory viruses were also impacted by COVID-19 mitigation approaches, we performed a molecular respiratory pathogen panel on nasopharyngeal (NP) swabs collected from symptomatic patients presenting to a drive-thru COVID-19 testing site between January 15 and April 15, 2021, who were negative for SARS-CoV-2.

MATERIALS AND METHODS

Study site and participants

Symptomatic patients tested for SARS-CoV-2 at the University of North Carolina Hospitals Respiratory Diagnostic Center (RDC) drive-thru testing site between January 15 and April 15, 2021, were included.³ Symptomatic patients were diverted from outpatient clinics to the RDC for testing during the study period. Patients were considered symptomatic if they reported one of the following symptoms: subjective fever, chills, severe fatigue, muscle aches,

* Address correspondence to Melissa B. Miller, PhD, Department of Pathology and Laboratory Medicine, UNC School of Medicine, Chapel Hill, NC.

E-mail address: melissa.miller@unchealth.unc.edu (M.B. Miller).

Conflicts of interest: All authors declare no conflicts of interest.

runny nose, sore throat, loss of taste or smell, cough, shortness of breath, nausea or vomiting, headache, abdominal pain, or diarrhea (≥ 3 loose stools in 24 hours).

Respiratory panel testing

NP swabs were initially tested for SARS-CoV-2 RNA by either Abbott Alinity m or Abbott m2000 EUA tests. Specimens that were negative and had remnant samples available were tested by a molecular respiratory panel. The BioFire RP 2.0 (bioMerieux, Durham, NC) is an FDA-cleared multiplex PCR panel that detects adenovirus, endemic coronaviruses (HKU1, NL63, 229E, OC43), metapneumovirus, rhinovirus and/or enterovirus, influenza A (A/H1, A/H3, A/H1-2009), influenza B, parainfluenza virus (PIV) 1, PIV2, PIV3, PIV4, respiratory syncytial virus, *Bordetella parapertussis*, *Bordetella pertussis*, *Chlamydia pneumoniae*, and *Mycoplasma pneumoniae*. The result of rhinovirus and/or enterovirus indicates the inability of the molecular panel to differentiate between these closely related viruses. Samples were stored in universal transport media at 4 °C if tested within 3 days of collection or frozen at -80 °C. Only 1 swab per patient was included in the study.

Hospital epidemiology data

Results of molecular respiratory testing from January 15 to April 15 in 2019, 2020, and 2021 were collated from outpatients, including emergency department patients, to compare positivity rates.

This study was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill.

RESULTS

During the study period, 15,149 outpatients were tested for SARS-CoV-2 through the RDC; 5,068 patients were symptomatic, with the remainder being asymptomatic and tested for exposure, prior to travel, or other reasons. Of the symptomatic patients, 433 (8.5%) tested positive for SARS-CoV-2. A remnant sample was available in the laboratory for 1,783 patients with undetectable SARS-CoV-2 RNA for additional testing by the molecular respiratory panel with 373 (20.9%) testing positive for at least 1 virus. Rhinovirus and/or enterovirus alone were detected in 329 (18.5%) samples. An additional nine specimens tested positive for rhinovirus and/or enterovirus and at least 1 other virus indicating a coinfection (RSV, n = 4; adenovirus, n = 4; or coronavirus NL63, n = 1; Fig 1). Endemic coronaviruses (229E, NL63, OC43) represented 18 single infections and 2 coinfections (Fig 1). Other viruses detected included adenovirus, RSV, PIV2, PIV3, and metapneumovirus. Influenza viruses and bacterial targets were not detected in any of the tested specimens.




Fig 1. Results from the respiratory pathogen panel for symptomatic outpatients at a COVID-19 testing center who tested negative for SARS-CoV-2 RNA. Number displayed is percent positivity.




Fig 2. Positivity rates by virus for outpatients tested by a molecular respiratory panel during January 15 to April 15 in 2019, 2020, and 2021. Number displayed is percent positivity.

Patients seen at outpatient facilities during the 2021 study period had 5,459 molecular respiratory tests performed with the largest number being positive for rhinovirus and/or enterovirus (n = 80), followed by RSV (n = 17) and adenovirus (n = 15) (Fig 2). Influenza viruses were not detected in these patients. In previous years (2019 and 2020) for the period, January 15 - April 15 percent positivity was higher across all virus types except rhinovirus and/or enterovirus and adenovirus. Notably, influenza B had a low level of circulation in 2019.² Outpatient respiratory viral testing volumes during the study months for 2019 and 2020 were 4,897 and 7,392, respectively.

DISCUSSION

Although the decrease in transmission of influenza is multifactorial, the implementation of mitigation strategies to decrease SARS-CoV-2 transmission likely played a significant role. The continued detection of rhinovirus and/or enterovirus and not influenza during the SARS-CoV-2 Alpha surge suggests that the transmissibility of these respiratory viruses differs, as does their ability to be prevented. In comparing the positivity rate of specimens collected from outpatients tested over the same months for the prior 3 years, the proportion that was positive for rhinovirus and/or enterovirus was slightly increased in 2021. This is in contrast to all the other tested viruses that either dropped significantly (influenza, RSV, and others) or stayed the same (adenovirus) (Fig 2). Our observed trend in rhinovirus and/or enterovirus detections is also mirrored in national syndromic trend data for the same time period.⁴

Our results suggest that while some respiratory viruses, such as influenza, are likely to be mitigated through implementing infection prevention measures such as changes in social behavior, other viruses such as rhinovirus and/or enterovirus may continue to propagate. Much of the emphasis on COVID-19 mitigation measures has been on preventing respiratory aerosols and droplets from spreading SARS-CoV-2 with relatively less attention paid to the transmission that occurs via contaminated surfaces. Enveloped viruses such as influenza and SARS-CoV-2 are readily inactivated by routine disinfectants and handwashing, whereas non-enveloped viruses such as rhinovirus and/or enterovirus are more refractory to these measures.⁵ Therefore, our data may represent the continued transmission of viruses by surfaces during times of enhanced respiratory hygiene (ie, masking, distancing).

Throughout the COVID-19 pandemic, the reduction of non-SARS-CoV-2 respiratory viruses has been demonstrated throughout the world.^{6–10} Even though respiratory viruses continued to circulate, the implemented mitigation measures likely helped to limit the spread of the majority of respiratory viruses compared to previous seasons. Our findings suggest that the use of non-pharmaceutical prevention measures to reduce the spread of respiratory viruses should be considered for high-risk institutions such as hospitals and nursing homes during periods of peak community transmission. Overall, these results provide support for the adoption of COVID-19 prevention strategies to limit the transmission of other respiratory viral pathogens, especially those most vulnerable to adverse clinical outcomes of infection.

References

1. Centers for Disease Control and Prevention. 2021. 2020–2021 Flu Season summary. Accessed April 14, 2022. <https://www.cdc.gov/flu/season/faq-flu-season-2020-2021>.
2. Centers for Disease Control and Prevention. 2017–2019. National, regional, and state level outpatient illness and viral surveillance. Accessed April 14, 2022. <https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>.
3. Wohl DA, Barzin AH, Napravnik S, et al. COVID-19 symptoms at time of testing and association with positivity among outpatients tested for SARS-CoV-2. *PLoS One*. 2021;16:e0260879.
4. BioFire Diagnostics. BioFire syndromic trends. Accessed April 14, 2022. <https://www.cdc.gov/flu/season/faq-flu-season-2020-2021.htm>.
5. Lin Q, Lim JYC, Xue K, et al. Sanitizing agents for virus inactivation and disinfection. *View (Beijing)*. 2020;1:e16.
6. Amaddeo A, Cason C, Cozzi G, Ronfani L, Comar M. Social distancing measures for COVID-19 are changing winter season. *Arch Dis Child*. 2021;106:e47.
7. Huang QS, Wood T, Jelley L, et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. *Nat Commun*. 2021;12:1001.
8. Ippolito G, La Vecchia A, Umbrello G, et al. Disappearance of seasonal respiratory viruses in children under two years old during COVID-19 pandemic: a monocentric retrospective study in Milan, Italy. *Front Pediatr*. 2021;9:721005.
9. Redlberger-Fritz M, Kundi M, Aberle SW, Puchhammer-Stockl E. Significant impact of nationwide SARS-CoV-2 lockdown measures on the circulation of other respiratory virus infections in Austria. *J Clin Virol*. 2021;137:104795.
10. Tang JW, Bialasiewicz S, Dwyer DE, et al. Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. *J Med Virol*. 2021;93:4099–4101.